natco pharma semaglutide to Launch Generic Injection in India in March 2026 Natco Pharma partners with Eris

This is particularly meaningful for patients who have pre-existing liver conditions and for whom alcohol-induced liver damage is a clinical concern

Patients undergoing tirzepatide therapy commonly experience: Improved blood pressure: reductions in systolic and diastolic blood pressure have been observed across tirzepatide clinical trials Better cholesterol profiles: reductions in LDL and triglycerides, with improvements in HDL Improved blood glucose regulation: tirzepatide significantly improves insulin sensitivity and reduces fasting glucose, even in patients without diabetes Reduction in waist circumference: visceral fat reduction, which is directly associated with reduced cardiovascular and metabolic risk Preservation of lean muscle mass: unlike traditional caloric restriction, which often results in 2530% of weight loss coming from muscle, tirzepatide promotes preferential fat loss Potential hormonal benefits: emerging evidence suggests that fat mass reduction lowers aromatase activity, which may support healthier testosterone-to-estrogen balance For patients managing multiple metabolic conditions simultaneously, GLP-1/GIP weight loss therapy represents an opportunity to address root causes, rather than individual symptoms, through a single medically supervised intervention

[206] Some studies have suggested possible associations with certain birth defects, while others have not found such associations

I add this both for my patients who are on GLP-1 or aren't

FDAs Tentative Approval of the same program earlier this year

During weight loss on semaglutide, aim for 1.2-1.6 grams of protein per kilogram of body weight daily to help preserve lean muscle mass and prevent weakness